Sectors & Industries HealthcareDiagnostics & Research
Best Diagnostic & Research Stocks to Buy Now (2025)
Top diagnostic & research stocks in 2025 ranked by overall Zen Rating. "A" Rated stocks have returned an average of +32.52% per year, and are the best diagnostic & research stocks to buy now. Learn More.

Industry: Diagnostics & Research

Overview Zen Rating Price Value Growth Financials Momentum Sentiment

Diagnostics & Research is Zen Rated B and is the 37th ranked industry out of 145 stock market industries

Ticker	Company	Market Cap	Shares	Institutional %	Insider %	Net Insider (L12M)	Net Insider (L3M)
SHC	SOTERA HEALTH CO	$4.55B	284,093,929	76.81%	23.19%	Net Selling	Net Selling
IDXX	IDEXX LABORATORIES INC	$56.01B	79,851,330	93.11%	1.78%	Net Buying	Net Buying
A	AGILENT TECHNOLOGIES INC	$41.64B	283,500,427	89.86%	1.24%	Net Buying	Net Selling
ILMN	ILLUMINA INC	$18.33B	152,800,000	93.38%	6.62%	Net Selling	Net Selling
CDNA	CAREDX INC	$816.24M	51,432,639	78.07%	21.93%	Net Selling	Net Buying
MEDP	MEDPACE HOLDINGS INC	$16.66B	28,168,223	28.65%	71.35%	Net Buying	Net Selling
QGEN	QIAGEN NV	$9.72B	217,685,000	76.05%	0.00%
CRL	CHARLES RIVER LABORATORIES INTERNATIONAL INC	$8.33B	49,215,471	96.60%	3.40%	Net Buying	Net Buying
PRE	PRENETICS GLOBAL LTD	$187.17M	13,895,394	8.31%	0.00%
CAI	CARIS LIFE SCIENCES INC	$6.86B	282,146,923	33.64%	66.36%	Net Selling	Net Buying
TMO	THERMO FISHER SCIENTIFIC INC	$217.96B	375,708,059	88.94%	0.89%	Net Selling	Net Selling
BNR	BURNING ROCK BIOTECH LTD	$121.90M	107,682,818	1.34%	0.00%
LH	LABCORP HOLDINGS INC	$22.21B	82,900,000	96.46%	1.52%	Net Selling	Net Selling
PRPO	PRECIPIO INC	$31.61M	1,619,584	0.37%	99.63%	Net Buying	Net Selling
FLGT	FULGENT GENETICS INC	$914.70M	30,912,392	52.60%	41.79%	Net Selling	Net Selling
DHR	DANAHER CORP	$156.24B	706,349,563	75.82%	24.18%	Net Selling	Net Selling
IQV	IQVIA HOLDINGS INC	$38.00B	170,000,000	53.94%	46.06%	Net Selling	Net Buying
MTD	METTLER TOLEDO INTERNATIONAL INC	$28.85B	20,428,445	95.55%	4.45%	Net Selling	Net Buying
DGX	QUEST DIAGNOSTICS INC	$20.87B	111,242,362	96.27%	1.77%	Net Selling	Net Selling
EXAS	EXACT SCIENCES CORP	$12.84B	189,471,298	94.85%	3.31%	Net Selling	Net Selling
NEOG	NEOGEN CORP	$1.38B	217,298,626	98.04%	1.96%	Net Buying	Net Buying
MYGN	MYRIAD GENETICS INC	$591.91M	93,213,722	91.28%	8.72%	Net Selling	Net Selling
WAT	WATERS CORP	$22.58B	59,534,740	92.35%	7.65%	Net Selling	Net Buying
BLLN	BILLIONTOONE INC	N/A	44,015,279	0.00%	26.68%	Net Buying	Net Buying
TWST	TWIST BIOSCIENCE CORP	$1.80B	60,360,925	88.39%	11.61%	Net Selling	Net Selling
XGN	EXAGEN INC	$211.90M	22,663,099	40.38%	49.06%	Net Selling	Net Selling
NEO	NEOGENOMICS INC	$1.30B	129,387,801	72.46%	27.54%	Net Buying	Net Selling
CSTL	CASTLE BIOSCIENCES INC	$995.92M	29,188,659	85.70%	14.30%	Net Selling	Net Selling
RVTY	REVVITY INC	$10.59B	113,375,621	97.29%	2.71%	Net Selling	Net Selling
GH	GUARDANT HEALTH INC	$11.86B	126,041,089	66.63%	33.37%	Net Selling	Net Selling
ICLR	ICON PLC	$12.48B	76,359,932	99.45%	0.00%
ACRS	ACLARIS THERAPEUTICS INC	$251.36M	108,345,239	58.78%	41.22%	Net Buying
GRAL	GRAIL INC	$3.24B	38,982,223	67.29%	23.99%	Net Selling	Net Selling
RDNT	RADNET INC	$5.67B	77,146,342	69.84%	30.16%	Net Selling	Net Selling
BDSX	BIODESIX INC	$62.85M	7,955,685	47.28%	52.72%	Net Buying	Net Buying
NTRA	NATERA INC	$27.70B	138,014,465	80.29%	19.71%	Net Selling	Net Selling
MDXH	MDXHEALTH SA	$19.65M	49,497,334	23.06%	76.94%
OPK	OPKO HEALTH INC	$982.66M	767,701,280	20.70%	79.30%	Net Buying	Net Buying
PSNL	PERSONALIS INC	$674.91M	88,804,348	62.61%	37.39%	Net Selling	Net Selling
NOTV	INOTIV INC	$36.07M	34,352,978	24.51%	39.40%	Net Buying	Net Buying
DRIO	DARIOHEALTH CORP	$22.57M	2,274,848	33.64%	66.36%	Net Buying	Net Buying
STIM	NEURONETICS INC	$139.71M	68,485,922	26.42%	31.60%	Net Selling
ISPC	ISPECIMEN INC	$3.43M	5,539,345	1.03%	98.97%
LAB	STANDARD BIOTOOLS INC	$461.48M	384,565,414	54.17%	45.83%	Net Buying	Net Buying
BIAF	BIOAFFINITY TECHNOLOGIES INC	$1.78M	948,944	7.01%	92.99%
BNBX	APPLIED DNA SCIENCES INC	$4.02M	1,291,465	0.68%	99.32%
SERA	SERA PROGNOSTICS INC	$112.28M	38,061,868	48.89%	25.64%	Net Selling	Net Selling
FONR	FONAR CORP	$97.01M	6,585,978	44.38%	3.58%
TRIB	TRINITY BIOTECH PLC	$15.27M	359,193,482	0.71%	0.00%
IMDX	INSIGHT MOLECULAR DIAGNOSTICS INC	$225.02M	28,664,437	15.70%	84.30%	Net Buying	Net Selling
PRPH	PROPHASE LABS INC	$10.47M	41,541,205	6.45%	24.84%
VNRX	VOLITIONRX LTD	$38.09M	107,595,421	22.29%	35.39%	Net Buying	Net Buying
NDRA	ENDRA LIFE SCIENCES INC	$4.95M	752,755	0.42%	99.58%	Net Buying	Net Buying
MYNZ	MAINZ BIOMED NV	$5.97M	4,091,853	9.42%	0.00%
XWEL	XWELL INC	$4.78M	5,756,703	1.23%	98.77%
ADVB	ADVANCED BIOMED INC	$9.69M	21,640,000	0.61%	0.00%
CHEK	CHECK-CAP LTD	$9.89M	5,850,906	2.02%	0.00%

Diagnostic & Research Stocks FAQ

What are the best diagnostic & research stocks to buy right now in Nov 2025?

According to Zen Ratings, our proprietary rating system that evaluates 115 factors proven to drive growth in stocks and assigns each stock in our system an overall letter grade as well as 7 individual Component Grades for Value, Growth, Momentum, Sentiment, Safety, Financials, and proprietary AI algorithms, the 3 best diagnostic & research stocks to buy right now are:

1. Sotera Health Co (NASDAQ:SHC)

Sotera Health Co (NASDAQ:SHC) is the #1 top diagnostic & research stock out of 57 with a Zen Rating of A. Stocks with a rating of A have had an average return of +32.52% per year. Learn more.

The Component Grade breakdown for Sotera Health Co (NASDAQ:SHC) is: Value: C, Growth: A, Momentum: C, Sentiment: A, Safety: B, Financials: C, and AI: C.

Sotera Health Co (NASDAQ:SHC) has a Due Diligence Score of 24, which is -2 points lower than the diagnostic & research industry average of 26. Although this number is below the industry average, our proven quant model rates SHC as a "A".

SHC passed 8 out of 33 due diligence checks and has weak fundamentals. Sotera Health Co has seen its stock return 4.5% over the past year, underperforming other diagnostic & research stocks by -6 percentage points.

Sotera Health Co has an average 1 year price target of $18.00, an upside of 12.43% from Sotera Health Co's current stock price of $16.01.

Sotera Health Co stock has a consensus Buy recommendation according to Wall Street analysts. Of the 4 analysts covering Sotera Health Co, 25% have issued a Strong Buy rating, 25% have issued a Buy, 50% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

2. Idexx Laboratories (NASDAQ:IDXX)

Idexx Laboratories (NASDAQ:IDXX) is the #2 top diagnostic & research stock out of 57 with a Zen Rating of A. Stocks with a rating of A have had an average return of +32.52% per year. Learn more.

The Component Grade breakdown for Idexx Laboratories (NASDAQ:IDXX) is: Value: C, Growth: C, Momentum: B, Sentiment: B, Safety: C, Financials: A, and AI: B.

Idexx Laboratories (NASDAQ:IDXX) has a Due Diligence Score of 50, which is 24 points higher than the diagnostic & research industry average of 26.

IDXX passed 17 out of 33 due diligence checks and has strong fundamentals. Idexx Laboratories has seen its stock return 63.2% over the past year, overperforming other diagnostic & research stocks by 53 percentage points.

Idexx Laboratories has an average 1 year price target of $737.14, an upside of 5.08% from Idexx Laboratories's current stock price of $701.48.

Idexx Laboratories stock has a consensus Strong Buy recommendation according to Wall Street analysts. Of the 7 analysts covering Idexx Laboratories, 57.14% have issued a Strong Buy rating, 14.29% have issued a Buy, 28.57% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

3. Agilent Technologies (NYSE:A)

Agilent Technologies (NYSE:A) is the #3 top diagnostic & research stock out of 57 with a Zen Rating of B. Stocks with a rating of B have had an average return of +19.88% per year. Learn more.

The Component Grade breakdown for Agilent Technologies (NYSE:A) is: Value: B, Growth: C, Momentum: C, Sentiment: C, Safety: A, Financials: B, and AI: C.

Agilent Technologies (NYSE:A) has a Due Diligence Score of 39, which is 13 points higher than the diagnostic & research industry average of 26.

A passed 14 out of 38 due diligence checks and has average fundamentals. Agilent Technologies has seen its stock return 9.39% over the past year, underperforming other diagnostic & research stocks by -1 percentage points.

Agilent Technologies has an average 1 year price target of $152.90, an upside of 4.09% from Agilent Technologies's current stock price of $146.89.

Agilent Technologies stock has a consensus Strong Buy recommendation according to Wall Street analysts. Of the 10 analysts covering Agilent Technologies, 60% have issued a Strong Buy rating, 10% have issued a Buy, 30% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

What are the diagnostic & research stocks with highest dividends?

Out of 6 diagnostic & research stocks that have issued dividends in the past year, the 3 diagnostic & research stocks with the highest dividend yields are:

1. Quest Diagnostics (NYSE:DGX)

Quest Diagnostics (NYSE:DGX) has an annual dividend yield of 1.28%, which is 1 percentage points higher than the diagnostic & research industry average of 0.63%. Quest Diagnostics's dividend payout is stable, having never dropped by more than 10% in the last 10 years. Quest Diagnostics's dividend has shown consistent growth over the last 10 years.

Quest Diagnostics's dividend payout ratio of 27.2% indicates that its dividend yield is sustainable for the long-term.

2. Labcorp Holdings (NYSE:LH)

Labcorp Holdings (NYSE:LH) has an annual dividend yield of 1.08%, which is the same as the diagnostic & research industry average of 0.63%. Labcorp Holdings's dividend payout is stable, having never dropped by more than 10% in the last 10 years. Labcorp Holdings's dividend has not shown consistent growth over the last 10 years.

Labcorp Holdings's dividend payout ratio of 28.1% indicates that its dividend yield is sustainable for the long-term.

3. Agilent Technologies (NYSE:A)

Agilent Technologies (NYSE:A) has an annual dividend yield of 0.51%, which is the same as the diagnostic & research industry average of 0.63%. Agilent Technologies's dividend payout is stable, having never dropped by more than 10% in the last 10 years. Agilent Technologies's dividend has shown consistent growth over the last 10 years.

Agilent Technologies's dividend payout ratio of 22.9% indicates that its dividend yield is sustainable for the long-term.

Why are diagnostic & research stocks down?

Diagnostic & research stocks were down -1.74% in the last day, and up 0.58% over the last week. Grail was the among the top losers in the diagnostics & research industry, dropping -1.85% yesterday.

GRAL stock has given up its prior gain. GRAIL shares were trading higher after the company reported better-than-expected Q3 financial results.

What are the most undervalued diagnostic & research stocks?

Based on the Valuation rating, one of the 7 components of a stocks overall Zen Ratings grade, which evaluates factors including estimated earnings yield, earnings before interest and taxes/enterprise value, cash flow yield, free cash flow to price, and price-to-earnings growth (PEG ratio), the 3 most undervalued diagnostic & research stocks right now are:

1. Qiagen Nv (NYSE:QGEN)

Qiagen Nv (NYSE:QGEN) is the most undervalued diagnostic & research stock based on its Valuation Rating of B. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

Qiagen Nv has a valuation score of 43, which is 29 points higher than the diagnostic & research industry average of 14. It passed 3 out of 7 valuation due diligence checks.

Qiagen Nv's stock has gained 4.74% in the past year. It has underperformed other stocks in the diagnostic & research industry by -6 percentage points.

2. Icon (NASDAQ:ICLR)

Icon (NASDAQ:ICLR) is the second most undervalued diagnostic & research stock based on its Valuation Rating of B. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

Icon has a valuation score of 57, which is 43 points higher than the diagnostic & research industry average of 14. It passed 4 out of 7 valuation due diligence checks.

Icon's stock has dropped -19.84% in the past year. It has underperformed other stocks in the diagnostic & research industry by -30 percentage points.

3. Revvity (NYSE:RVTY)

Revvity (NYSE:RVTY) is the third most undervalued diagnostic & research stock based on its Valuation Rating of B. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

Revvity has a valuation score of 14, which is 0 points higher than the diagnostic & research industry average of 14. It passed 1 out of 7 valuation due diligence checks.

Revvity's stock has dropped -22% in the past year. It has underperformed other stocks in the diagnostic & research industry by -33 percentage points.

Are diagnostic & research stocks a good buy now?

61.9% of diagnostic & research stocks rated by analysts are a strong buy right now. On average, analysts expect diagnostic & research stocks to rise by 6.16% over the next year.

4.35% of diagnostic & research stocks have a Zen Rating of A (Strong Buy), 26.09% of diagnostic & research stocks are rated B (Buy), 60.87% are rated C (Hold), 2.17% are rated D (Sell), and 6.52% are rated F (Strong Sell).

What is the average p/e ratio of the diagnostics & research industry?

The average P/E ratio of the diagnostics & research industry is 24.73x.

WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.

Diagnostic & Research Stocks FAQ

1. Sotera Health Co (NASDAQ:SHC)

2. Idexx Laboratories (NASDAQ:IDXX)

3. Agilent Technologies (NYSE:A)

1. Quest Diagnostics (NYSE:DGX)

2. Labcorp Holdings (NYSE:LH)

3. Agilent Technologies (NYSE:A)

1. Qiagen Nv (NYSE:QGEN)

2. Icon (NASDAQ:ICLR)

3. Revvity (NYSE:RVTY)

Company

Stock Tools

Stock Ideas